Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation

被引:16
作者
Bryson, JS
Jennings, CD
Caywood, BE
Dix, AR
Lowery, DM
Kaplan, AM
机构
[1] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT PATHOL,LEXINGTON,KY 40536
[2] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT IMMUNOL & MICROBIOL,LEXINGTON,KY 40536
[3] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,MARKEY CANC CTR,LEXINGTON,KY 40536
关键词
bone marrow transplantation; recipient age; graft-versus-host disease;
D O I
10.1038/sj.bmt.1700719
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The incidence and severity of GVHD following bone marrow transplantation increases with recipient age. The role of recipient age on the development of GVHD was analyzed in a semi-allogeneic (C57BL/6 --> (C57BL/6 x DBA/2)F1) murine GVHD system, Young adult (2 months) and old (12-14 months) recipient mice were lethally irradiated and reconstituted with young adult T cell-depleted bone marrow (ATBM) or ATBM and young spleen cells, A significantly higher percentage of old vs young recipients developed lethal GVHD, Furthermore, while pre-transplant conditioning with irradiation was not required to observe increased mortality in old recipients, irradiation predisposed the older animals for a more severe course of GVHD, suggesting that GVHD occurred in old compared to young animals in the absence of pre-transplant conditioning but was exacerbated by irradiation, Histologically, the immunological responses in the GVHD target organs were more severe in the old GVHD animals, In support of this observation, increased spontaneous proliferation was observed using lymphoid cells isolated from old vs young GVHD mice, These findings demonstrate that old recipients develop a more severe course of GVHD following BMT, and may present a unique opportunity to study age-related factors in the generation of GVHD.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 30 条
  • [1] ANTIN JH, 1992, BLOOD, V80, P2964
  • [2] BONE-MARROW TRANSPLANTATION
    ARMITAGE, JO
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) : 827 - 838
  • [3] BANDINI G, 1991, BONE MARROW TRANSPL, V7, P251
  • [4] PHASE-I STUDY OF BUSULFAN AND CYCLOPHOSPHAMIDE IN PREPARATION FOR ALLOGENEIC MARROW TRANSPLANT FOR PATIENTS WITH MULTIPLE-MYELOMA
    BENSINGER, WI
    BUCKNER, CD
    CLIFT, RA
    PETERSEN, FB
    BIANCO, JA
    SINGER, JW
    APPELBAUM, FR
    DALTON, W
    BEATTY, P
    FEFER, A
    STORB, R
    THOMAS, ED
    HANSEN, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (09) : 1492 - 1497
  • [5] BORTIN MM, 1987, PROGR BONE MARROW TR, P243
  • [6] BUCKNER CD, 1989, EUR J HAEMATOL, V43, P186
  • [7] DAYNES RA, 1993, J IMMUNOL, V150, P5219
  • [8] FERRARA JLM, 1991, NEW ENGL J MED, V324, P667
  • [9] ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA
    GAHRTON, G
    TURA, S
    LJUNGMAN, P
    BELANGER, C
    BRANDT, L
    CAVO, M
    FACON, T
    GRANENA, A
    GORE, M
    GRATWOHL, A
    LOWENBERG, B
    NIKOSKELAINEN, J
    REIFFERS, JJ
    SAMSON, D
    VERDONCK, L
    VOLIN, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (18) : 1267 - 1273
  • [10] GAHRTON G, 1994, BONE MARROW TRANSPL, P640